Popular GLP-1 Drugs Are Shaping Health Beyond Weight Loss & Diabetes
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.
Popular GLP-1 medications may have health benefits that extend beyond weight loss and blood sugar control, a new study finds
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the risks of substance abuse disorders, psychosis, infections, some kinds of cancer and dementia,
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders,
GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks
A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits,
Variety of GLP-1 Drugs Help People Without Diabetes Lose Weight: Review
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
28 benefits, 16 risks: How popular GLP-1 weight loss drugs reshape human health – for better and worse
Discover the unexpected health benefits of diabetes and weight loss medications like Ozempic and Wegovy. Find out how these medications may reduce addiction risk and protect against Alzheimer's.
Not Just For Weight Loss: GLP-1 Drugs May Affect Addiction And Dementia Risk
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
GLP-1 weight loss drugs linked to a wide range of health benefits and risks: study
A new peer-reviewed study based on data from nearly 2M individuals highlights a wide range of clinical benefits and risks, including several newly found conditions linked to the GLP-1 class of weight loss and diabetes drugs.
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s disease
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
GLP-1 drugs linked to lower dementia risk, higher risk of kidney, stomach issues
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Health Care Up on GLP-1 Alzheimer's Data -- Health Care Roundup
Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...
Hosted on MSN18h
GLP-1 drugs like Ozempic and Wegovy lower the risk of 42 conditions
The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...
News Medical on MSN1d
Researchers create an atlas of health associations for GLP-1 receptor agonists
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
STAT1d
What can’t GLP-1s do? Study maps benefits while warning of uncommon risks
GLP-1 drugs like Ozempic have swept the world as effective therapies for far more than their original target of diabetes.